메뉴 건너뛰기




Volumn 8, Issue 10, 2012, Pages 569-578

Anticoagulants in atrial fibrillation patients with chronic kidney disease

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; DABIGATRAN ETEXILATE; EDOXABAN; RIVAROXABAN; WARFARIN; XIMELAGATRAN;

EID: 84867022051     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2012.160     Document Type: Review
Times cited : (76)

References (75)
  • 1
    • 64549104914 scopus 로고    scopus 로고
    • Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation. The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study
    • for the ATRIA Study Investigators
    • Go, A. S., et al. for the ATRIA Study Investigators. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation. The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. Circulation 119, 1363-1369 (2009).
    • (2009) Circulation , vol.119 , pp. 1363-1369
    • Go, A.S.1
  • 2
    • 77952988390 scopus 로고    scopus 로고
    • Chronic kidney disease and prevalent atrial fibrillation: The Chronic Renal Insufficiency Cohort (CRIC)
    • Soliman, E. Z., et al. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am. Heart J. 159, 1102-1107 (2010).
    • (2010) Am. Heart J. , vol.159 , pp. 1102-1107
    • Soliman, E.Z.1
  • 3
    • 79953769563 scopus 로고    scopus 로고
    • Association of chronic kidney disease with atrial fibrillation among adults in the United States: Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study
    • Baber, U., et al. Association of chronic kidney disease with atrial fibrillation among adults in the United States: Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Circ. Arrhythm. Electrophysiol. 4, 26-32 (2011).
    • (2011) Circ. Arrhythm. Electrophysiol. , vol.4 , pp. 26-32
    • Baber, U.1
  • 4
    • 77950880770 scopus 로고    scopus 로고
    • New anticoagulants
    • Eikelboom, J. W. & Weitz, J. I. New anticoagulants. Circulation 121, 1523-1532 (2010).
    • (2010) Circulation , vol.121 , pp. 1523-1532
    • Eikelboom, J.W.1    Weitz, J.I.2
  • 5
    • 84857438475 scopus 로고    scopus 로고
    • New oral anticoagulants should not be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation
    • Ansell, J. New oral anticoagulants should not be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation. Circulation 125, 165-170 (2012).
    • (2012) Circulation , vol.125 , pp. 165-170
    • Ansell, J.1
  • 6
    • 84855402737 scopus 로고    scopus 로고
    • Newer oral anticoagulants should be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism
    • Granger, C. B. & Armaganijan, L. V. Newer oral anticoagulants should be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism. Circulation 125, 159-164 (2012).
    • (2012) Circulation , vol.125 , pp. 159-164
    • Granger, C.B.1    Armaganijan, L.V.2
  • 7
    • 65649145705 scopus 로고    scopus 로고
    • Effect of clopidogrel added to aspirin in patients with atrial fibrillation
    • The ACTIVE Investigators
    • The ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N. Engl. J. Med. 360, 2066-2078 (2009).
    • (2009) N. Engl. J. Med. , vol.360 , pp. 2066-2078
  • 8
    • 33744945247 scopus 로고    scopus 로고
    • Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): A randomised controlled trial
    • Connolly, S., et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367, 1903-1912 (2006).
    • (2006) Lancet , vol.367 , pp. 1903-1912
    • Connolly, S.1
  • 9
    • 70349306707 scopus 로고    scopus 로고
    • Dabigatran versus warfarin in patients with atrial fibrillation
    • Connolly, S. J., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361, 1139-1151 (2009).
    • (2009) N. Engl. J. Med. , vol.361 , pp. 1139-1151
    • Connolly, S.J.1
  • 10
    • 79952301326 scopus 로고    scopus 로고
    • Apixaban in patients with atrial fibrillation
    • for the AVERROES Steering Committee and Investigators
    • Connolly, S. J., et al. for the AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N. Engl. J. Med. 364, 806-817 (2011).
    • (2011) N. Engl. J. Med. , vol.364 , pp. 806-817
    • Connolly, S.J.1
  • 11
    • 80052592404 scopus 로고    scopus 로고
    • Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
    • Patel, M. R., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365, 883-891 (2011).
    • (2011) N. Engl. J. Med. , vol.365 , pp. 883-891
    • Patel, M.R.1
  • 12
    • 80052825103 scopus 로고    scopus 로고
    • Apixaban versus warfarin in patients with atrial fibrillation
    • for the ARISTOTLE Committees and Investigators
    • Granger, C. B., et al. for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365, 981-992 (2011).
    • (2011) N. Engl. J. Med. , vol.365 , pp. 981-992
    • Granger, C.B.1
  • 13
    • 0345414673 scopus 로고    scopus 로고
    • Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): Randomised controlled trial
    • Executive Steering Committee on behalf of the SPORTIF III Investigators
    • Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 362, 1691-1698 (2003).
    • (2003) Lancet , vol.362 , pp. 1691-1698
  • 14
    • 13444309949 scopus 로고    scopus 로고
    • Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: A randomized trial
    • SPORTIF Executive Steering Committee for the SPORTIF V Investigators
    • SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 293, 690-698 (2005).
    • (2005) JAMA , vol.293 , pp. 690-698
  • 15
    • 77957932391 scopus 로고    scopus 로고
    • Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis in Myocardial Infarction study 48 (ENGAGE AF TIMI 48)
    • Ruff, C. T., et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF TIMI 48). Am. Heart J. 160, 635-641 (2010).
    • (2010) Am. Heart J. , vol.160 , pp. 635-641
    • Ruff, C.T.1
  • 16
    • 84859971855 scopus 로고    scopus 로고
    • Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors
    • Kaatz, S., et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am. J. Hematol. 87 (Suppl. 1), S141-S145 (2012).
    • (2012) Am. J. Hematol. , vol.87 , Issue.SUPPL. 1
    • Kaatz, S.1
  • 17
    • 84861616750 scopus 로고    scopus 로고
    • Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: The RE LY trial
    • Hart, R. G., et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE LY trial. Stroke 43, 1511-1517 (2012).
    • (2012) Stroke , vol.43 , pp. 1511-1517
    • Hart, R.G.1
  • 18
    • 84857853180 scopus 로고    scopus 로고
    • Bleeding risk with dabigatran in the frail elderly
    • Harper, P., Young, L. & Merriman, E. Bleeding risk with dabigatran in the frail elderly. N. Engl. J. Med. 366, 864-866 (2012).
    • (2012) N. Engl. J. Med. , vol.366 , pp. 864-866
    • Harper, P.1    Young, L.2    Merriman, E.3
  • 20
    • 57149140461 scopus 로고    scopus 로고
    • Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range
    • on behalf of the ACTIVE W Investigators
    • Connolly, S. J., et al. on behalf of the ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 118, 2029-2037 (2008).
    • (2008) Circulation , vol.118 , pp. 2029-2037
    • Connolly, S.J.1
  • 21
    • 33847006936 scopus 로고    scopus 로고
    • Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: Results from SPORTIF III and v
    • White, H. D., et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch. Intern. Med. 167, 239-245 (2007).
    • (2007) Arch. Intern. Med. , vol.167 , pp. 239-245
    • White, H.D.1
  • 22
    • 15844410955 scopus 로고    scopus 로고
    • Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvular atrial fibrillation: A record linkage study in a large British population
    • Jones, M., et al. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvular atrial fibrillation: a record linkage study in a large British population. Heart 91, 472-477 (2005).
    • (2005) Heart , vol.91 , pp. 472-477
    • Jones, M.1
  • 23
    • 65449163045 scopus 로고    scopus 로고
    • Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States
    • Baker, W. L., Cios, D. A., Sander, S. D. & Coleman, C. I. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J. Manag. Care Pharm. 15, 244-252 (2009).
    • (2009) J. Manag. Care Pharm. , vol.15 , pp. 244-252
    • Baker, W.L.1    Cios, D.A.2    Sander, S.D.3    Coleman, C.I.4
  • 24
    • 52449129321 scopus 로고    scopus 로고
    • Warfarin for atrial fibrillation in community-based practise
    • Rose, A. J., Ozonoff, A., Henault, L. E. & Hylek, E. M. Warfarin for atrial fibrillation in community-based practise. J. Thromb. Haemost. 6, 1647-1654 (2008).
    • (2008) J. Thromb. Haemost. , vol.6 , pp. 1647-1654
    • Rose, A.J.1    Ozonoff, A.2    Henault, L.E.3    Hylek, E.M.4
  • 25
    • 80054071757 scopus 로고    scopus 로고
    • Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment
    • Fox, K. A., et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur. Heart J. 32, 2387-2394 (2011).
    • (2011) Eur. Heart J. , vol.32 , pp. 2387-2394
    • Fox, K.A.1
  • 26
    • 34548509436 scopus 로고    scopus 로고
    • Atrial fibrillation in haemodialysis patients: Do guidelines for anticoagulation apply?
    • To, A. C., Yehia, M. & Collins, J. F. Atrial fibrillation in haemodialysis patients: do guidelines for anticoagulation apply? Nephrology (Carlton) 12, 441-447 (2007).
    • (2007) Nephrology (Carlton) , vol.12 , pp. 441-447
    • To, A.C.1    Yehia, M.2    Collins, J.F.3
  • 27
    • 65249178935 scopus 로고    scopus 로고
    • Kidney function influences warfarin responsiveness and hemorrhagic complications
    • Limdi, N. A., et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. J. Am. Soc. Nephrol. 20, 912-921 (2009).
    • (2009) J. Am. Soc. Nephrol. , vol.20 , pp. 912-921
    • Limdi, N.A.1
  • 28
    • 0036707888 scopus 로고    scopus 로고
    • Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: A randomized controlled trial
    • Crowther, M. A., et al. Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: a randomized controlled trial. J. Am. Soc. Nephrol. 13, 2331-2337 (2002).
    • (2002) J. Am. Soc. Nephrol. , vol.13 , pp. 2331-2337
    • Crowther, M.A.1
  • 29
    • 84879799019 scopus 로고    scopus 로고
    • Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease
    • in press
    • Eikelboom, J. W., et al. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. J. Stroke Cerebrovasc. Dis. (in press).
    • J. Stroke Cerebrovasc. Dis.
    • Eikelboom, J.W.1
  • 30
    • 80655139710 scopus 로고    scopus 로고
    • Warfarin in atrial fibrillation patients with moderate chronic kidney disease
    • Hart, R. G., Pearce, L. A., Asinger, R. W. & Herzog, C. A. Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin. J. Am. Soc. Nephrol. 6, 2599-2604 (2011).
    • (2011) Clin. J. Am. Soc. Nephrol. , vol.6 , pp. 2599-2604
    • Hart, R.G.1    Pearce, L.A.2    Asinger, R.W.3    Herzog, C.A.4
  • 31
    • 79952316518 scopus 로고    scopus 로고
    • Chronic kidney disease and CHADS2 score independently predict cardiovascular events and mortality in patients with nonvalvular atrial fibrillation
    • Nakagawa, K., et al. Chronic kidney disease and CHADS2 score independently predict cardiovascular events and mortality in patients with nonvalvular atrial fibrillation. Am. J. Cardiol. 107, 912-916 (2011).
    • (2011) Am. J. Cardiol. , vol.107 , pp. 912-916
    • Nakagawa, K.1
  • 32
    • 0035854054 scopus 로고    scopus 로고
    • Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation
    • Gage, B. F., et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285, 2864-2870 (2001).
    • (2001) JAMA , vol.285 , pp. 2864-2870
    • Gage, B.F.1
  • 33
    • 34548455445 scopus 로고    scopus 로고
    • Independent predictors of stroke in patients with atrial fibrillation: A systematic review
    • Stroke Risk in Atrial Fibrillation Working Group
    • Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 69, 546-554 (2007).
    • (2007) Neurology , vol.69 , pp. 546-554
  • 34
    • 78650878679 scopus 로고    scopus 로고
    • Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: The HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score
    • Lip, G. Y., Frison, L., Halperin, J. L. & Lane, D. A. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J. Am. Coll. Cardiol. 57, 173-180 (2011).
    • (2011) J. Am. Coll. Cardiol. , vol.57 , pp. 173-180
    • Lip, G.Y.1    Frison, L.2    Halperin, J.L.3    Lane, D.A.4
  • 35
    • 33751255101 scopus 로고    scopus 로고
    • Development of a contemporary bleeding risk model for elderly warfarin recipients
    • Shireman, T. I., et al. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest 130, 1390-1396 (2006).
    • (2006) Chest , vol.130 , pp. 1390-1396
    • Shireman, T.I.1
  • 36
    • 80052094564 scopus 로고    scopus 로고
    • A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study
    • Fang, M. C., et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J. Am. Coll. Cardiol. 58, 395-401 (2011).
    • (2011) J. Am. Coll. Cardiol. , vol.58 , pp. 395-401
    • Fang, M.C.1
  • 37
    • 33344461585 scopus 로고    scopus 로고
    • Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF)
    • Gage, B. F., et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am. Heart J. 151, 713-719 (2006).
    • (2006) Am. Heart J. , vol.151 , pp. 713-719
    • Gage, B.F.1
  • 38
    • 80055079237 scopus 로고    scopus 로고
    • Risk of bleeding with oral anticoagulants: An updated systematic review and performance analysis of clinical prediction rules
    • Loewen, P. & Dahri, K. Risk of bleeding with oral anticoagulants: an updated systematic review and performance analysis of clinical prediction rules. Ann. Hematol. 90, 1191-1200 (2011).
    • (2011) Ann. Hematol. , vol.90 , pp. 1191-1200
    • Loewen, P.1    Dahri, K.2
  • 39
    • 0016916438 scopus 로고
    • Prediction of creatinine clearance from serum creatinine
    • Cockcroft, D. W. & Gault, M. H. Prediction of creatinine clearance from serum creatinine. Nephron 16, 31-41 (1976).
    • (1976) Nephron , vol.16 , pp. 31-41
    • Cockcroft, D.W.1    Gault, M.H.2
  • 40
    • 84879799310 scopus 로고    scopus 로고
    • U. S. Food and Drug Administration and Dabigatran Briefing Document [online]
    • U. S. Food and Drug Administration. Dabigatran Briefing Document [online], http://www.fda.gov/downloads/advisorycommittees/ committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ ucm226009.pdf (2010).
    • (2010)
  • 41
    • 79958126202 scopus 로고    scopus 로고
    • Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial
    • Eikelboom, J. W., et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial. Circulation 123, 2363-2372 (2011).
    • (2011) Circulation , vol.123 , pp. 2363-2372
    • Eikelboom, J.W.1
  • 43
    • 72449133295 scopus 로고    scopus 로고
    • U. S. Food and Drug Administration
    • U. S. Food and Drug Administration. FDA approved drug products: Xarelto [online], http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm? fuseaction=Search.Overview&DrugName=XARELTO (2011).
    • (2011) FDA Approved Drug Products: Xarelto [Online]
  • 44
    • 84879798911 scopus 로고    scopus 로고
    • Health Canada. Drugs and Health Products: Pradax [online]
    • Health Canada. Drugs and Health Products: Pradax [online], http://webprod3.hc-sc.gc.ca/noc-ac/info.do?lang=eng&no=11817 (2010).
    • (2010)
  • 45
    • 84879796711 scopus 로고    scopus 로고
    • Health Canada. Drugs Health Products: Xarelto [online]
    • Health Canada. Drugs and Health Products: Xarelto [online], http://webprod3.hc-sc.gc.ca/noc-ac/info.do?lang=eng&no=12966 (2012).
    • (2012)
  • 46
    • 84879795107 scopus 로고    scopus 로고
    • European Medicines Agency. Product information: Pradaxa [online]
    • European Medicines Agency. Product information: Pradaxa [online], http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000829/WC500041059.pdf (2012).
    • (2012)
  • 47
    • 84879794134 scopus 로고    scopus 로고
    • European Medicines Agency. Product information: Xarelto [online]
    • European Medicines Agency. Product information: Xarelto [online], http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000944/WC500057108.pdf (2012).
    • (2012)
  • 48
    • 77949421739 scopus 로고    scopus 로고
    • Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: An open-label, parallel-group, single-centre study
    • Stangier, J., Rathgen, K., Stähle, H. & Mazur, D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin. Pharmacokinet. 49, 259-268 (2010).
    • (2010) Clin. Pharmacokinet. , vol.49 , pp. 259-268
    • Stangier, J.1    Rathgen, K.2    Stähle, H.3    Mazur, D.4
  • 49
    • 84858595913 scopus 로고    scopus 로고
    • Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: Recommendations for stroke prevention and rate/rhythm control
    • Skanes, A. C., et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can. J. Cardiol. 28, 125-136 (2012).
    • (2012) Can. J. Cardiol. , vol.28 , pp. 125-136
    • Skanes, A.C.1
  • 50
    • 84857759555 scopus 로고    scopus 로고
    • Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding
    • Warkentin, T. E., et al. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 119, 2172-2174 (2012).
    • (2012) Blood , vol.119 , pp. 2172-2174
    • Warkentin, T.E.1
  • 51
    • 77953168824 scopus 로고    scopus 로고
    • Dabigatran etexilate - A novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity
    • van Ryn, J., et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb. Haemost. 103, 1116-1127 (2010).
    • (2010) Thromb. Haemost. , vol.103 , pp. 1116-1127
    • Van Ryn, J.1
  • 52
    • 70349908012 scopus 로고    scopus 로고
    • Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation
    • Chan, K. E., Lazarus, J. M., Thadhani, R. & Hakim, R. M. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J. Am. Soc. Nephrol. 20, 2223-2233 (2009).
    • (2009) J. Am. Soc. Nephrol. , vol.20 , pp. 2223-2233
    • Chan, K.E.1    Lazarus, J.M.2    Thadhani, R.3    Hakim, R.M.4
  • 53
    • 27144535900 scopus 로고    scopus 로고
    • Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients
    • Genovesi, S., et al. Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients. Am. J. Kidney Dis. 46, 897-902 (2005).
    • (2005) Am. J. Kidney Dis. , vol.46 , pp. 897-902
    • Genovesi, S.1
  • 54
    • 84857095835 scopus 로고    scopus 로고
    • The prevalence of and factors associated with chronic atrial fibrillation in Medicare/Medicaid-eligible dialysis patients
    • Wetmore, J. B., et al. The prevalence of and factors associated with chronic atrial fibrillation in Medicare/Medicaid-eligible dialysis patients. Kidney Int. 81, 469-476 (2012).
    • (2012) Kidney Int. , vol.81 , pp. 469-476
    • Wetmore, J.B.1
  • 55
    • 0141794137 scopus 로고    scopus 로고
    • Comparison of prognostic value of atrial fibrillation versus sinus rhythm in patients on long-term hemodialysis
    • Vázquez, E., et al. Comparison of prognostic value of atrial fibrillation versus sinus rhythm in patients on long-term hemodialysis. Am. J. Cardiol. 92, 868-871 (2003).
    • (2003) Am. J. Cardiol. , vol.92 , pp. 868-871
    • Vázquez, E.1
  • 56
    • 77956897768 scopus 로고    scopus 로고
    • Atrial fibrillation in hemodialysis patients: Clinical features and associations with anticoagulant therapy
    • Wizemann, V., et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int. 77, 1098-1106 (2010).
    • (2010) Kidney Int , vol.77 , pp. 1098-1106
    • Wizemann, V.1
  • 57
    • 38149077292 scopus 로고    scopus 로고
    • Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients
    • Genovesi, S., et al. Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients. Am. J. Kidney Dis. 51, 255-262 (2008).
    • (2008) Am. J. Kidney Dis. , vol.51 , pp. 255-262
    • Genovesi, S.1
  • 58
    • 80755152863 scopus 로고    scopus 로고
    • Effectiveness and safety of warfarin initiation in older hemodialysis patients with atrial fibrillation
    • Winkelmayer, W. C., Liu, J., Setoguchi, S. & Choudry, N. K. Effectiveness and safety of warfarin initiation in older hemodialysis patients with atrial fibrillation. Clin. J. Am. Soc. Nephrol. 6, 2662-2668 (2011).
    • (2011) Clin. J. Am. Soc. Nephrol. , vol.6 , pp. 2662-2668
    • Winkelmayer, W.C.1    Liu, J.2    Setoguchi, S.3    Choudry, N.K.4
  • 59
    • 77950267229 scopus 로고    scopus 로고
    • Outcome of atrial fibrillation among patients with end-stage renal disease
    • Chou, C. Y., et al. Outcome of atrial fibrillation among patients with end-stage renal disease. Nephrol. Dial. Transplant. 25, 1225-1230 (2010).
    • (2010) Nephrol. Dial. Transplant. , vol.25 , pp. 1225-1230
    • Chou, C.Y.1
  • 60
    • 0031801103 scopus 로고    scopus 로고
    • Risk of major hemorrhage for outpatients treated with warfarin
    • McMahon, D. A., Smith, D. M., Carey, M. A. & Zhou, X. H. Risk of major hemorrhage for outpatients treated with warfarin. J. Gen. Intern. Med. 13, 311-316 (1998).
    • (1998) J. Gen. Intern. Med. , vol.13 , pp. 311-316
    • McMahon, D.A.1    Smith, D.M.2    Carey, M.A.3    Zhou, X.H.4
  • 61
    • 34548047713 scopus 로고    scopus 로고
    • Warfarin anticoagulation in hemodialysis patients: A systematic review of bleeding rates
    • Elliott, M. J., Zimmerman, D. & Holden, R. M. Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates. Am. J. Kidney Dis. 50, 433-440 (2007).
    • (2007) Am. J. Kidney Dis. , vol.50 , pp. 433-440
    • Elliott, M.J.1    Zimmerman, D.2    Holden, R.M.3
  • 63
    • 34748904679 scopus 로고    scopus 로고
    • Vascular calcification in chronic kidney disease: The role of vitamin K
    • Holden, R. M. & Booth, S. L. Vascular calcification in chronic kidney disease: the role of vitamin K. Nat. Clin. Pract. Nephrol. 3, 522-523 (2007).
    • (2007) Nat. Clin. Pract. Nephrol. , vol.3 , pp. 522-523
    • Holden, R.M.1    Booth, S.L.2
  • 64
    • 34347394385 scopus 로고    scopus 로고
    • Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation
    • Hart, R. G., Pearce, L. A. & Aguilar, M. I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med. 146, 857-867 (2007).
    • (2007) Ann. Intern. Med. , vol.146 , pp. 857-867
    • Hart, R.G.1    Pearce, L.A.2    Aguilar, M.I.3
  • 65
    • 23844465424 scopus 로고    scopus 로고
    • K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients
    • K/DOQI Workgroup
    • K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am. J. Kidney Dis. 45, S1-S153 (2005).
    • (2005) Am. J. Kidney Dis. , vol.45
  • 66
    • 65349189718 scopus 로고    scopus 로고
    • Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients
    • Chan, K. E., Lazarus, J. M., Thadhani, R. & Hakim, R. M. Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. J. Am. Soc. Nephrol. 20, 872-881 (2009).
    • (2009) J. Am. Soc. Nephrol. , vol.20 , pp. 872-881
    • Chan, K.E.1    Lazarus, J.M.2    Thadhani, R.3    Hakim, R.M.4
  • 67
    • 78649336758 scopus 로고    scopus 로고
    • Warfarin in haemodialysis patients with atrial fibrillation: What benefit?
    • Yang, F., Chou, D., Schweitzer, P. & Hanon, S. Warfarin in haemodialysis patients with atrial fibrillation: what benefit? Europace 12, 1666-1672 (2010).
    • (2010) Europace , vol.12 , pp. 1666-1672
    • Yang, F.1    Chou, D.2    Schweitzer, P.3    Hanon, S.4
  • 68
    • 79952662118 scopus 로고    scopus 로고
    • Severe renal impairment and stroke prevention in atrial fibrillation: Implications for thromboprophylaxis and bleeding risk
    • Marinigh, R., Lane, D. A. & Lip, G. Y. Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J. Am. Coll. Cardiol. 57, 1339-1348 (2011).
    • (2011) J. Am. Coll. Cardiol. , vol.57 , pp. 1339-1348
    • Marinigh, R.1    Lane, D.A.2    Lip, G.Y.3
  • 69
    • 80052296951 scopus 로고    scopus 로고
    • Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)
    • Herzog, C. A., et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 80, 572-586 (2011).
    • (2011) Kidney Int , vol.80 , pp. 572-586
    • Herzog, C.A.1
  • 71
    • 65649142017 scopus 로고    scopus 로고
    • For the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate
    • Levey, A. S., et al. for the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150, 604-612 (2009).
    • (2009) Ann. Intern. Med. , vol.150 , pp. 604-612
    • Levey, A.S.1
  • 72
    • 84855854046 scopus 로고    scopus 로고
    • Chronic kidney disease
    • Levey, A. S. & Coresh, J. Chronic kidney disease. Lancet 379, 165-180 (2012).
    • (2012) Lancet , vol.379 , pp. 165-180
    • Levey, A.S.1    Coresh, J.2
  • 73
    • 33744958852 scopus 로고    scopus 로고
    • Assessing kidney function - Measured and estimated glomerular filtration rate
    • Stevens, L. A., Coresh, J., Greene, T. & Levey, A. S. Assessing kidney function - measured and estimated glomerular filtration rate. N. Engl. J. Med. 354, 2473-2483 (2006).
    • (2006) N. Engl. J. Med. , vol.354 , pp. 2473-2483
    • Stevens, L.A.1    Coresh, J.2    Greene, T.3    Levey, A.S.4
  • 74
    • 0033574249 scopus 로고    scopus 로고
    • A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation
    • Modification of Diet in Renal Disease Study Group
    • Levey, A. S., et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann. Intern. Med. 130, 461-470 (1999).
    • (1999) Ann. Intern. Med. , vol.130 , pp. 461-470
    • Levey, A.S.1
  • 75
    • 0036234755 scopus 로고    scopus 로고
    • Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate
    • Coresh, J., et al. Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am. J. Kidney Dis. 39, 920-929 (2002).
    • (2002) Am. J. Kidney Dis. , vol.39 , pp. 920-929
    • Coresh, J.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.